The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical
Research Funding - MSD (Inst); Novartis (Inst)
A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan).
 
Haruyasu Murakami
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - AstraZeneca; Novartis
Speakers' Bureau - AstraZeneca
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Shigeki Umemura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Meiji Seika Kaisha
Research Funding - MSD (Inst)
 
Masahiro Shinoda
No Relationships to Disclose
 
Masato Shingyoji
No Relationships to Disclose
 
Yukari Ogawa
No Relationships to Disclose
 
Koji Takeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Oncology (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Kaname Nosaki
No Relationships to Disclose
 
Norio Okamoto
Speakers' Bureau - AstraZeneca Japan
 
Hiromi Aono
No Relationships to Disclose
 
Satoshi Hara
No Relationships to Disclose
 
Shoichi Kuyama
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Meiji Seika Kaisha; Nippon Boehringer Ingelheim; Ono Pharmaceutical
 
Akiko Sato
No Relationships to Disclose
 
Nobuhiro Kanaji
No Relationships to Disclose
 
Tamio Okimoto
No Relationships to Disclose
 
Yuki Kataoka
Research Funding - Lilly (Inst)
 
Shingo Matsumoto
Honoraria - Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hibiki Udagawa
No Relationships to Disclose
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst)
 
Katsuya Tsuchihara
Honoraria - Takeda
 
Koichi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Life Technologies; Lilly; Merck Serono; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; SRL Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo
Research Funding - Abbvie; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda